PyrAmes Health develops continuous noninvasive blood pressure (cNIBP) monitoring platforms for patients across all ages. The Boppli platform provides accurate, wireless cNIBP for neonatal and pediatric patients, offering an alternative to invasive arterial lines. The Bosimi platforms serve adult inpatient, emergency care, and home medical management needs with cNIBP diagnostics and treatment validation.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVFounders
Product
Problem
Invasive arterial lines, the current gold standard for continuous blood pressure monitoring, carry risks and are not suitable for all patients. Intermittent cuff-based measurements are non-invasive but provide only sporadic readings, potentially missing critical blood pressure fluctuations. This is especially problematic in neonatal and critical care settings where continuous, accurate blood pressure monitoring is essential for timely intervention.
Solution
PyrAmes offers a continuous, non-invasive blood pressure (cNIBP) monitoring solution using a flexible, paper-thin sensor and wireless technology. The Boppli platform is designed for patients of all ages, including newborns, and provides accurate, real-time blood pressure readings without the need for invasive procedures. This technology aims to improve patient safety and outcomes by enabling early detection of critical conditions and facilitating timely treatment adjustments. The Bosimi platform extends this cNIBP technology to adult inpatient, emergency care, and home medical management settings.
Target Audience
The primary target audience includes neonatal intensive care units (NICUs), hospitals, emergency care providers, and patients requiring continuous blood pressure monitoring at home.
Features
- Boppli Platform: cNIBP for neonatal and pediatric patients, offering a non-invasive alternative to arterial lines.
- Bosimi Platform: cNIBP for adult inpatient and emergency care settings.
- Bosimi@Home Platform: cNIBP for diagnostics, treatment validation, and home medical management.
- Wireless data transmission for real-time monitoring and analysis.
- FDA 510(k) clearance for the Boppli platform, validating its safety and accuracy.
- Breakthrough Device Designation from the FDA, recognizing its potential to improve outcomes in critical care.